GHRP-6

GHRP-6 is a synthetic hexapeptide and met-enkephalin analog that stimulates endogenous GH release. It acts through GHS-R1a (growth hormone secretagogue receptor) and CD36 scavenger receptor, which are widely expressed, including in cardiovascular tissues.

GH Secretion: 2.1–7.9 fold increase in PI turnover; 1,434 ± 393× baseline GH release; synergistic GHRH potentiation up to 3,771 ± 399×
Musculoskeletal / Body Composition: Increased fat-free mass; reduced bone turnover
Cardioprotection: Prevention of doxorubicin-induced cardiomyopathy and systolic dysfunction
Cytoprotection: Multi-organ protection: cardiac, neuronal, gastrointestinal, hepatic; reduced ROS; enhanced antioxidant defenses
Anti-fibrotic: Upregulation of prosurvival Bcl-2; inhibition of fibrotic pathways
Sleep / Recovery: Enhanced REM and stage 4 slow-wave sleep
Synergistic GH Effects: Amplifies endogenous pulsatile GH when combined with GHRH

Berlanga-Acosta J, et al. Synthetic growth hormone-releasing peptides (GHRPs): A historical appraisal of the evidences supporting their cytoprotective effects. Clin Med Insights Cardiol. 2017;11:1179546817694558.
Popovic V, et al. Blocked GHRP-6-induced GH secretion and absence of synergy with GHRH in hypothalamopituitary disconnection. J Clin Endocrinol Metab. 1995;80(9):2723–2727.
Adams EF, et al. GHRP-6 stimulates phosphatidylinositol turnover in human pituitary somatotroph cells. J Endocrinol. 1995;145(1):35–41.
Berlanga-Acosta J, et al. GHRP-6 prevents doxorubicin-induced myocardial and extra-myocardial damage via prosurvival mechanisms. Front Pharmacol. 2024;15:1402138.
Nass R, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults. Ann Intern Med. 2008;149(9):601–611.

$53.00

Per Unit

In stock